Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme (GBM), the most malignant cancer of the brain. Specifically, the study, led by Professor H. Phillip […]
This post first appeared on Biotechin.asia – Your Daily Biotech And Healthca, please read the originial post: here